XTalks

JANUARY 29, 2025

Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. And when it comes to weight loss, change is good, it ends off saying.

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. Though as we anticipated, we believe it will likely be relegated to later-line, post-biologics setting given lesser efficacy and safety baggage.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

JANUARY 9, 2024

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105

Hormones Antibody Trials Production 105

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. billion in 2021 to $61.6 billion by 2030.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

JANUARY 16, 2025

It is a complication of Graves disease, an immune system condition that causes the thyroid gland to make excess amounts of thyroid hormone. Slings upcoming Phase III trial will provide further insights into the safety and efficacy of the molecule, as it gears up to compete with Amgen in the thyroid eye disease market.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

XTalks

JULY 19, 2024

The GLP-1 drug market is on its way to becoming one of the most lucrative pharmaceutical markets. Morgan has estimated that the GLP-1 market will surpass $100 billion by 2030, with growth driven equally by use for diabetes and obesity. If you want your company to be featured on Xtalks.com, please email ayeshar@xtalks.com.

Pharmacy 104

Pharmacy Drugs Production Sales 104

XTalks

SEPTEMBER 6, 2024

For the international market, Novartis will continue to partner with external isotope suppliers. Lutathera is used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut and hindgut.

Development 105

Development Manufacturing Marketing Hormones 105

XTalks

MARCH 6, 2023

The portfolio contains approximately forty-five commercial products, four products in the pipeline, and forty approved non-marketed products, many of which are generics focused on women’s health. Some of the higher-value approved products include contraceptives, such as hormonal vaginal rings and birth control pills.

Production 98

Production Branding Dermatology Hormones 98

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

XTalks

MARCH 8, 2021

And now the tirzepatide results could help Lilly continue its market march if it wins approval for it. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. Semaglutide acts by inhibiting glucagon, which is a hormone that increases blood sugar.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

MARCH 22, 2021

The mega biotech acquisition deals, ranging between a quarter to over half a billion dollars, reflects the expanding oncology market, which was valued at $136.7 Despite setbacks due to the pandemic, the market is expected to recover and continue its march forward. The liquid biopsy market itself was valued at over $1.06

Life Science 110

Life Science Development Marketing Gene Expression 110

XTalks

NOVEMBER 10, 2021

Darbepoetin alfa is a synthetic version of the hormone erythropoietin, which is made in the kidneys and stimulates the production of red blood cells (RBC), or erythrocytes. Kidney dysfunction in CKD leads to impaired production of the hormone, particularly in more advanced disease. Market Size and Regulatory Pathway.

Trials 97

Trials Hormones Drugs FDA Approval 97

XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. Hormone-based therapeutics aim to delay glaucoma progression by enhancing estrogen’s potential protective effects.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. Biogen and Denali will co-market the lead LRRK2 product in the US and China, and Biogen will commercialise in all other markets.

Marketing 93

Marketing Gene Gene Silencing Drugs 93

XTalks

NOVEMBER 3, 2022

Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1). In its first quarter on the market since its approval, sales totalled $97 million between July and September in the US.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

NOVEMBER 5, 2024

The shares began trading on the Nasdaq Global Market (Nasdaq: SEPN) on October 25, 2024, with a successful closing completed on October 30, 2024. SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance. Gross proceeds from the offering reached $331.2 million patients in the US.

Drugs 59

Drugs Hormones Protein Antibody 59

pharmaphorum

NOVEMBER 27, 2022

Incidents such as the hormone replacement therapy drug shortage in early 2022 have shown the damaging impact supply chain issues can have on people who depend on these drugs. This means batch sizes can be tailored to daily demands rather than market forecasts. About the author.

Production 105

Production Manufacturing Drugs Marketing 105

XTalks

JULY 26, 2024

The tablet consists of two hormones: norethindrone acetate, a type of progestin, and ethinyl estradiol, a synthetic form of estrogen. Together, these hormones work to prevent ovulation, alter the uterine lining and thicken cervical mucus, making it more difficult for sperm to reach the egg and for a fertilized egg to implant in the uterus.

FDA Approval 52

FDA Approval Hormones Containment Drugs 52

pharmaphorum

FEBRUARY 3, 2022

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post looks at dealing with sudden stress and turning it into positive energy. Visualise success. About the author.

Life Science 98

Life Science Hormones Sales Marketing 98

XTalks

APRIL 29, 2022

Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

FEBRUARY 3, 2023

Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

Roots Analysis

MARCH 21, 2022

Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades. Subcutaneous biologics – current market landscape. Our Social Media Platform. Web: [link]. LinkedIn: [link].

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Drugs 52

XTalks

DECEMBER 5, 2024

Unlike the reigning blockbuster GLP-1 drugs on the market namely Novo Nordisks Wegovy (semaglutide) and Eli Lillys Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors Amgens MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 hormone) (..)

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

XTalks

AUGUST 22, 2024

Hypoparathyroidism arises when the parathyroid glands fail to produce enough parathyroid hormone (PTH) or when the PTH produced is ineffective. Ascendis Pharma’s shares climbed to 11 percent in pre-market trading post news of Yorvipath’s approval. Seventy-nine percent of patients (vs.

Hormones 52

Hormones FDA Approval Trials Clinical Trials 52

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

DECEMBER 5, 2024

Unlike the reigning blockbuster GLP-1 drugs on the market — namely Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors — Amgen’s MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 (..)

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

XTalks

MARCH 15, 2023

Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. from the previous year owing to the market entry of Strattera generics in the third quarter of 2017. It is predicted that the ADHD market is set to reach $16.9 In 2017, Strattera’s total revenue was $618.2

Drugs 98

Drugs Sales Trials Marketing 98

The Pharma Data

MARCH 11, 2021

Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”

Sales 52

Sales Gene Therapy Marketing Gene 52

XTalks

FEBRUARY 21, 2024

Recently, Eli Lilly revealed promising results from a mid-stage trial, indicating that its popular drug, tirzepatide (marketed as Zepbound and Mounjaro for weight loss and diabetes, respectively), may be an effective treatment for the fatty liver disease metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

OCTOBER 11, 2023

Rybelsus is Novo’s third semaglutide product on the market, a tablet form of the drug used for the treatment of type 2 diabetes. They mimic the action of GLP-1, a hormone that helps regulate blood sugar levels by enhancing insulin secretion.

Drugs 59

Drugs Insulin Hormones FDA Approval 59

Roots Analysis

JANUARY 23, 2024

The peptide therapeutics market has undergone substantial evolution since the inception of insulin. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

The Pharma Data

FEBRUARY 21, 2022

Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause. Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally.

Radiology 52

Radiology Cardiology Development Production 52

pharmaphorum

MARCH 11, 2021

Diagnostics was never a Cinderella sector; Britain has the fifth largest in vitro diagnostics (IVD) market in Europe, not gigantic but significant nevertheless. The theoretical value of this to a patient’s health, longevity and quality of life is enormous.

In-Vitro 69

In-Vitro Containment Radiology Life Science 69

XTalks

MARCH 25, 2024

They work by mimicking the action of the naturally occurring hormone GLP-1, which is involved in regulating blood sugar and appetite. GLP-1 receptor agonists, a class of drugs initially developed to treat type 2 diabetes, have been found to have significant effects on weight loss.

Drugs 105

Drugs Medicine Life Science Production 105

XTalks

NOVEMBER 9, 2023

Zepbound contains mimetics of the GLP-1 and GIP hormones that regulate appetite and blood sugar. The staggering billion-dollar figures reflect a growing obesity drug market that is projected to reach $100 billion by 2030, according to Goldman Sachs Research.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

XTalks

AUGUST 15, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday that the US Food and Drug Administration (FDA) has granted marketing authorization for its combination treatment Akeega for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.

FDA Approval 52

FDA Approval Gene Hormones Drugs 52

XTalks

MARCH 8, 2024

Despite the approvals, the market launches of Jubbonti and Wyost are uncertain due to ongoing patent litigation between Sandoz and Amgen. Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications. It occurs when the formation of new bone doesn’t keep up with the loss of old bone.

Drugs 59

Drugs FDA Approval Production Immune Response 59